

# Differential Control of Adrenal and Sympathetic Catecholamine Release by $\alpha_2$ -Adrenoceptor Subtypes

MARC BREDE, GÁBOR NAGY, MELANIE PHILIPP, JAKOB B. SØRENSEN, MARTIN J. LOHSE, AND LUTZ HEIN

*Institut für Pharmakologie und Toxikologie (M.B., M.P., M.J.L., L.H.), Universität Würzburg, 97078 Würzburg, Germany; and Max-Planck-Institut für Biophysikalische Chemie (G.N., J.B.S.), 37077 Göttingen, Germany*

In the adrenergic system, release of the neurotransmitter norepinephrine from sympathetic nerves is regulated by presynaptic inhibitory  $\alpha_2$ -adrenoceptors, but it is unknown whether release of epinephrine from the adrenal gland is controlled by a similar short feedback loop. Using gene-targeted mice we demonstrate that two distinct subtypes of  $\alpha_2$ -adrenoceptors control release of catecholamines from sympathetic nerves ( $\alpha_{2A}$ ) and from the adrenal medulla ( $\alpha_{2C}$ ). In isolated mouse chromaffin cells,  $\alpha_2$ -receptor activation inhibited the electrically stimulated increase in cell capacitance (a correlate of exocytosis), voltage-activated  $\text{Ca}^{2+}$  current, as well as secretion of epinephrine and norepinephrine. The inhibitory effects of  $\alpha_2$ -agonists on cell capacitance, voltage-activated  $\text{Ca}^{2+}$  currents, and on catecholamine secretion

were completely abolished in chromaffin cells isolated from  $\alpha_{2C}$ -receptor-deficient mice. *In vivo*, deletion of sympathetic or adrenal feedback control led to increased plasma and urine norepinephrine ( $\alpha_{2A}$ -knockout) and epinephrine levels ( $\alpha_{2C}$ -knockout), respectively. Loss of feedback inhibition was compensated by increased tyrosine hydroxylase activity, as detected by elevated tissue dihydroxyphenylalanine levels. Thus, receptor subtype diversity in the adrenergic system has emerged to selectively control sympathetic and adrenal catecholamine secretion via distinct  $\alpha_2$ -adrenoceptor subtypes. Short-loop feedback inhibition of epinephrine release from the adrenal gland may represent a novel therapeutic target for diseases that arise from enhanced adrenergic stimulation. (*Molecular Endocrinology* 17: 1640–1646, 2003)

**A**DRENOCEPTORS FORM THE interface between the endogenous catecholamines, epinephrine and norepinephrine, and a wide array of target cells in the body to mediate the biological effects of the sympathetic nervous system. To date, nine different adrenoceptor subtypes have been identified (three  $\alpha_1$ , three  $\alpha_2$ , three  $\beta$  receptors) (1). Transgenic mouse models have recently become very valuable in the identification of the physiological significance of individual adrenergic receptor subtypes *in vivo* (2–7).

The adrenergic system can be divided into three parts: adrenergic neurons in the central nervous system, sympathetic neurons that innervate many organs and tissues, and the adrenal medulla. Norepinephrine is the principal neurotransmitter of sympathetic neurons, whereas epinephrine, and to a smaller degree also its precursor norepinephrine, is secreted from the chromaffin cells of the adrenal medulla into the circulation (8). Thus, the actions of norepinephrine are mostly restricted to the sites of release from sympathetic nerves, whereas epinephrine acts as a hormone to activate cardiovascular and metabolic responses via the blood stream (9). As adrenal chromaffin cells

and sympathetic neurons are both derived from a common neural crest precursor (10), it may be hypothesized that both cell types share similar patterns of regulation, including feedback control of neurotransmitter release.

Norepinephrine released from sympathetic nerves not only activates adrenoceptors on effector cells, but also stimulates presynaptic adrenoceptors to inhibit further transmitter secretion (11, 12).  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenergic receptors were previously identified as presynaptic inhibitory receptors that control the release of norepinephrine from peripheral sympathetic nerves and central catecholaminergic neurons *in vitro* (13–15). Furthermore, the deletion of the  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenergic receptor subtypes caused increased susceptibility to development of heart failure after chronic pressure overload *in vivo* (16). In contrast, it is unknown at present whether secretion of catecholamines from the adrenal medulla is under similar feedback control. To assess the existence and physiological relevance of feedback regulation in the two limbs of the sympathetic system, we used mice lacking individual  $\alpha_2$ -adrenoceptor subtypes (14, 17). Here we demonstrate for the first time that two distinct  $\alpha_2$ -receptor subtypes control sympathetic nerve ( $\alpha_{2A}$ ) and adrenal ( $\alpha_{2C}$ ) catecholamine release and that autocrine feedback reg-

Abbreviations:  $[\text{Ca}^{2+}]_i$ , intracellular calcium concentration; L-dopa, 3-(3,4-dihydroxyphenyl)-L-alanine;  $\alpha_2$ -KO,  $\alpha_2$ -receptor knockout; WT, wild-type.

ulation of epinephrine secretion in the adrenal gland is necessary to control circulating epinephrine levels.

## RESULTS AND DISCUSSION


### Regulation of Plasma and Urine Catecholamine Levels by $\alpha_2$ -Adrenoceptors

Norepinephrine and epinephrine levels were determined in the plasma of anesthetized wild-type (WT) and  $\alpha_2$ -receptor knockout ( $\alpha_2$ -KO) mice. Surprisingly, plasma catecholamines were differentially affected by deletion of the different  $\alpha_2$ -receptor subtypes (Fig. 1). Deletion of the  $\alpha_{2A}$ -receptor led to increased plasma levels of norepinephrine whereas epinephrine concentrations were selectively elevated in  $\alpha_{2C}$ -receptor-deficient mice (Fig. 1B). These findings were confirmed in urine samples collected over a period of 24 h in awake, freely moving animals (Fig. 1, C and D). Excretion (24 h) of norepinephrine was increased by 155% in  $\alpha_{2A}$ -KO mice and epinephrine excretion was enhanced by 95% in  $\alpha_{2C}$ -KO animals. Urine volume did not differ between WT and  $\alpha_{2B}$ - or  $\alpha_{2C}$ -KO mice, but was significantly elevated in  $\alpha_{2A}$ -KO mice ( $+95 \pm 15\%$ ,  $\alpha_{2A}$ -KO vs. WT;  $P < 0.05$ ).

These observations suggest that secretion of catecholamines from peripheral sympathetic nerves and from the adrenal medulla is differentially regulated by  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenoceptors (Fig. 1). In the peripheral nervous system, epinephrine is exclusively synthesized by adrenal chromaffin cells, whereas sympathetic nerves are the primary source of circulating norepinephrine (9). Whereas  $\alpha_2$ -mediated feedback inhibition of sympathetic norepinephrine release has been well documented (for recent reviews, see Refs. 2, 18, and 19), it is unclear whether epinephrine secretion from adrenal chromaffin cells is subject to similar feedback regulation. Early reports suggested that high concentrations of circulating epinephrine can inhibit the secretion of catecholamines from perfused dog adrenals (20, 21), but studies on isolated adrenal chromaffin or pheochromocytoma cells have yielded conflicting results (22–25). Under certain experimental conditions, the nonselective  $\alpha$ -receptor antagonist, phenoxybenzamine, increased release of catecholamines from rat adrenal gland *in vivo* (26). However, it was suggested that this effect was due to activation of inhibitory  $\alpha$ -adrenoceptors on cholinergic nerve endings rather than by direct effects on chromaffin cells (12).

### Expression of $\alpha_{2C}$ -Adrenoceptors in Adrenal Chromaffin Cells


Before investigating the function of isolated mouse chromaffin cells, we analyzed adrenal histology and expression patterns of  $\alpha_2$ -adrenoceptor subtypes. Adrenal glands from male  $\alpha_{2C}$ -receptor-deficient mice were significantly larger than organs from WT or  $\alpha_{2A}$ -



**Fig. 1.** Plasma and Urine Catecholamine Levels in  $\alpha_2$ -Adrenoceptor-Deficient Mice

Norepinephrine (A and C) was found to be elevated in blood plasma (obtained under anesthesia) and in urine (collected in metabolic cages over 24 h) from mice lacking  $\alpha_{2A}$ -adrenoceptors as compared with WT mice. In contrast, epinephrine levels were significantly higher in  $\alpha_{2C}$ -adrenoceptor-deficient mice when compared with the other genotypes (B and D). These results suggest that  $\alpha_{2A}$ - and  $\alpha_{2C}$ -receptors differentially control catecholamine release from sympathetic nerves and from adrenal chromaffin cells, respectively (*schematic drawing*). \*,  $P < 0.05$ , KO vs. WT, means  $\pm$  SEM,  $n = 13$ –25.

or  $\alpha_{2B}$ -KO mice [ $\alpha_{2C}$ -KO adrenal weight:  $+31 \pm 8\%$  vs. WT;  $P < 0.05$ ;  $\alpha_{2C}$ -KO,  $n = 14$ ; WT,  $n = 12$ ]. Cross-sections of adrenal glands did not reveal any structural defects in specimens from  $\alpha_2$ -receptor-deficient mice (Fig. 2), except for mild hypertrophy of chromaffin cells from  $\alpha_{2C}$ -KO mice (Fig. 2C; cross-sectional area  $+28 \pm 5\%$ ,  $\alpha_{2C}$ -KO vs. WT). In isolated chromaffin cells from WT mice, only  $\alpha_{2C}$ -receptor mRNA expression could be readily detected (Fig. 2D).  $\alpha_{2A}$ - or  $\alpha_{2B}$ -receptor mRNA could not be amplified reproducibly from chromaffin cells that were either isolated from WT mice or from  $\alpha_{2C}$ -receptor-deficient animals (Fig. 2D). Thus, genetic deletion of the  $\alpha_{2C}$ -




**Fig. 2.** Adrenal Gland Morphology and  $\alpha_2$ -Adrenoceptor Expression in WT and  $\alpha_{2C}$ -Adrenoceptor-Deficient Mice

Cross-section through the adrenal gland of a male WT mouse (A) and high-magnifications of adrenal medulla chromaffin cells of WT (B) or  $\alpha_{2C}$ -KO (C) mice. Chromaffin cells in the adrenal cortex of  $\alpha_{2C}$ -KO mice showed normal morphology but appeared enlarged by 28% in their cross-sectional area as compared with WT cells (B vs. C). C, Adrenal cortex; M, adrenal medulla; arrow, border between adrenal cortex and medulla. Bars, 300  $\mu$ m (A); 5  $\mu$ m (B and C). D, Isolated chromaffin cells from WT mice expressed  $\alpha_{2C}$ -adrenoceptors as detected by RT-PCR but no  $\alpha_{2A}$ - or  $\alpha_{2B}$ -adrenoceptors. In  $\alpha_{2C}$ -deficient chromaffin cells, no compensatory expression of  $\alpha_{2A}$ - or  $\alpha_{2B}$ -receptor was detectable. As a possible control, RT-PCR signals for  $\alpha_{2A}$ -,  $\alpha_{2B}$ -, and  $\alpha_{2C}$ -receptors from WT mice at embryonic day 9.5 (E9.5) are shown (42). No signals were observed in the absence of reverse transcriptase (not shown). Lower panel, Ethidium bromide-stained gel of 18S and 28S RNA after extraction from cells.

receptor gene was not accompanied by a compensatory up-regulation of  $\alpha_{2A}$ - or  $\alpha_{2B}$ -receptor expression. In the human adrenal gland,  $\alpha_{2C}$ -adrenoceptors are also the predominating  $\alpha_2$ -receptor subtype (27, 28).

Tissue epinephrine and norepinephrine levels did not differ in adrenal glands from WT and  $\alpha_2$ -adrenoceptor-deficient mice (data not shown). However, 3-(3,4-dihydroxyphenyl)-L-alanine (L-dopa) content was significantly elevated in  $\alpha_{2C}$ -KO adrenal glands as compared with WT adrenals (Fig. 3A), reflecting an increased activity of tyrosine hydroxylase which catalyzes the initial rate-limiting step of catecholamine biosynthesis (9). Similarly, L-dopa levels were elevated in cardiac tissue from mice lacking the  $\alpha_{2A}$ -receptor subtype (Fig. 3B), confirming that increased catecholamine release from adrenal chromaffin cells or sympathetic nerves causes a compensatory increase in catecholamine biosynthesis.




**Fig. 3.** Elevated Tissue L-dopa Levels in  $\alpha_2$ -Adrenoceptor-Deficient Mice

Adrenal gland (A) and cardiac (B) concentrations of L-dopa were determined as an indicator of tyrosine hydroxylase activity. Adrenal L-dopa levels were selectively elevated in mice lacking  $\alpha_{2C}$ -adrenoceptors, whereas L-dopa in the heart was significantly increased only in  $\alpha_{2A}$ -KO mice. \*,  $P < 0.05$  KO vs. WT;  $n = 6$ –8 animals per genotype; means  $\pm$  SEM.

### In Vitro Regulation of Exocytosis and $\text{Ca}^{2+}$ Currents in Isolated Chromaffin Cells

To test whether in the mouse, adrenal  $\alpha_2$ -adrenoceptors can, in fact, inhibit catecholamine secretion, effects of  $\alpha_2$ -adrenergic receptor stimulation by norepinephrine and the non-subtype-selective  $\alpha_2$ -receptor agonist UK14,304 on isolated mouse chromaffin cells were investigated (Fig. 4). Using whole-cell capacitance measurements, we found that depolarization led to an increase in cell capacitance due to fusion of release-competent secretory vesicles with the plasma membrane in WT chromaffin cells (Fig. 4A). This ca-

pacitance increase could be significantly attenuated by the  $\alpha_2$ -receptor agonist UK14,304 (Fig. 4, B and F) or by norepinephrine (data not shown). Furthermore, UK14,304 decreased peak  $\text{Ca}^{2+}$  currents in WT chromaffin cells (Fig. 4, D and G). Without  $\alpha_2$ -receptor stimulation, depolarization-induced increases in cell capacitance and voltage-activated calcium currents did not differ between cells isolated from WT or  $\alpha_2\text{C}$ -deficient mice (Fig. 4, F and G). However, the inhibitory effects of the  $\alpha_2$ -agonist UK14,304 on both parameters were completely abolished in cells from  $\alpha_2\text{C}$ -deficient mice. Thus,  $\alpha_2$ -adrenergic receptor mediated inhibition of catecholamine secretion from chromaffin



**Fig. 4.** Inhibition of Exocytosis and Voltage-Activated Calcium Currents by  $\alpha_2\text{C}$ -Adrenoceptors in Mouse Adrenal Chromaffin Cells


Voltage protocol applied to stimulate secretion (A, upper panel) and a typical voltage clamp recording (A, lower panel). Average capacitance traces (B and C) and average  $\text{Ca}^{2+}$  currents evoked by ramp depolarization (D and E). UK,  $\alpha_2$ -Agonist UK14,304. In isolated WT mouse chromaffin cells, the  $\alpha_2$ -agonist UK14,304 inhibited the depolarization-evoked capacitance increase (B and F) as well as the peak  $\text{Ca}^{2+}$  current (D and G). The inhibitory effect of the  $\alpha_2$ -agonist on cell capacitance and calcium currents was completely abolished in chromaffin cells from  $\alpha_2\text{C}$ -receptor-deficient mice (C, E, F, and G). \*,  $P < 0.01$ , means  $\pm$  SEM (WT,  $n = 20$ ; WT + UK,  $n = 19$ ; KO,  $n = 22$ ; KO + UK,  $n = 22$ ).

cells likely proceeds by a  $\text{Ca}^{2+}$ -dependent process that is similar to the feedback inhibition observed in adrenergic nerve terminals.

The basal (prestimulus) intracellular calcium concentration  $[\text{Ca}^{2+}]_i$  regulates the number of fusion-competent vesicles (29, 30) and may also modify the size of calcium currents due to the resulting differences in driving force for calcium influx. To rule out the unlikely possibility that the differences seen between different genotypes in chromaffin cells were due to differences in basal  $[\text{Ca}^{2+}]_i$ , we monitored  $[\text{Ca}^{2+}]_i$  during the experiments described above by introducing the calcium-sensitive dye fura-2 into the cells through the patch pipette. Basal cytosolic calcium concentrations did not differ between genotypes and were not affected by  $\alpha_2$ -receptor stimulation ( $[\text{Ca}^{2+}]_i$  WT:  $145 \pm 26$  nM; WT + UK14,304:  $173 \pm 20$  nM;  $\alpha_{2C}$ -KO:  $147 \pm 23$  nM;  $\alpha_{2C}$ -KO + UK14,304:  $135 \pm 22$  nM).

### $\alpha_{2C}$ -Adrenergic Receptors Inhibit Adrenal Secretion of Epinephrine and Norepinephrine

Acetylcholine-stimulated secretion of epinephrine could be inhibited by the  $\alpha_2$ -agonist UK14,304 in chromaffin cells from WT,  $\alpha_{2A}$ -KO, and  $\alpha_{2B}$ -KO mice but not in cells from  $\alpha_{2C}$ -deficient mice (Fig. 5). Similarly, the secretion of norepinephrine from isolated chromaffin cells was inhibited by an  $\alpha_2$ -agonist in WT cells but not in  $\alpha_{2C}$ -receptor-deficient cells (not shown). In WT chromaffin cells, epinephrine secretion induced by 80 mM  $\text{K}^+$ -mediated depolarization was inhibited by the  $\alpha_2$ -agonist UK14,304 by  $72 \pm 9\%$ . Basal catecholamine release and the degree of acetylcholine-induced stimulation of release did not differ between WT and  $\alpha_2$ -KO chromaffin cells (not shown). These findings demonstrate that in isolated chromaffin cells as in the adrenal, the  $\alpha_{2C}$ -adrenergic receptor subtype is the dominant regulator of catecholamine secretion. Due to their slower deactivation kinetics and higher



**Fig. 5.** Inhibition of Epinephrine Secretion by  $\alpha_{2C}$ -Adrenoceptors in Mouse Adrenal Chromaffin Cells

Acetylcholine-induced epinephrine secretion from WT or  $\alpha_{2A}$ -KO and  $\alpha_{2B}$ -KO chromaffin cells was inhibited by the  $\alpha_2$ -agonist UK14,304. In chromaffin cells from  $\alpha_{2C}$ -KO mice, no effect of the  $\alpha_2$ -receptor agonist was observed ( $n = 4-6$ ). \*  $P < 0.05$ , agonist vs. control; means  $\pm$  SEM.

affinity for catecholamines (31),  $\alpha_{2C}$ -receptors may be ideal receptors to sense and control the hormone epinephrine, whereas low-affinity  $\alpha_{2A}$ -receptors act as fast inhibitory regulators at the sympathetic nerve terminals (14, 32). Taken together, these results not only confirm that the  $\alpha_{2A}$ -subtype is the predominant receptor involved in the presynaptic regulation of norepinephrine from sympathetic nerves, but also definitively establish that the  $\alpha_{2C}$ -adrenergic receptor is an essential feedback regulator of epinephrine release from the adrenal gland.

The regulatory mechanism by which  $\alpha_{2C}$ -receptors control epinephrine secretion from chromaffin cells includes, at least, inhibition of calcium channels. The pathway is therefore most likely similar to the feedback mechanism that operates in adrenergic neurons:  $\alpha_{2C}$ -adrenoceptors that are localized in the plasma membrane activate inhibitory G proteins ( $G_{i/o}$ ).  $\beta\gamma$ -Subunits released from G proteins may directly inhibit voltage-gated calcium channels (41). However, further studies are required to test whether additional intracellular pathways contribute to  $\alpha_{2C}$ -receptor-mediated feedback regulation of epinephrine secretion. For example, in the present study we have not addressed the question of whether vesicle maturation (*e.g.* the number of fusion-competent vesicles) may also be regulated by  $\alpha_{2C}$ -receptor-mediated feedback.

### Conclusions

This is, to our knowledge, the first report demonstrating that  $\alpha_{2C}$ -adrenoceptors control secretion of the stress hormone epinephrine via an autocrine feedback loop in adrenal chromaffin cells and that genetic disruption of this feedback mechanism leads to enhanced blood levels of epinephrine.

The paradigm for endocrine feedback control is the hypothalamic-pituitary system, which releases tropic hormones to control peripheral endocrine glands, including the gonads, thyroid gland, and adrenal cortex. The conventional view is that hormones produced in the peripheral organs (*e.g.* glucocorticoids, thyroid hormone) feed back on the release of the hypothalamic-pituitary tropic hormones (*e.g.* CRH, TRH) via a long feedback circuit. However, recent experimental evidence suggests that, even in these systems, ultrashort feedback loops operate to control the tropic hormones, *e.g.* TRH inhibits its own synthesis (33). Ultrashort feedback control of GnRH may actually be required for pulsatile secretion of GnRH release from hypothalamic neurons (34). These examples illustrate that short and long feedback circuits operate together in the regulation of endocrine secretion. In this regulatory network, short feedback loops may have greater physiological and pathophysiological relevance than previously appreciated. Thus,  $\alpha_{2C}$ -adrenoceptors may represent novel therapeutic targets to attenuate or prevent the development of diseases that arise from overactivity of the adrenergic system.

## MATERIALS AND METHODS

### $\alpha_2$ -Adrenoceptor-Deficient Mice

The generation of the mouse lines lacking  $\alpha_2$ -adrenoceptor subtypes has been described previously (13, 17, 35). All animal procedures were approved by the responsible university and government authorities (Protocol No. 621-2531.01-28/01).

### Catecholamine Determination

Catecholamines were measured in plasma obtained from tribromoethanol-anesthetized mice, from urine samples that were collected over a 24-h period in metabolic cages, or from the supernatant of chromaffin cells cultured *in vitro*. Adrenal and cardiac catecholamine levels were determined after extraction as described previously (13). Epinephrine, norepinephrine, and L-dopa were quantified by HPLC combined with electrochemical detection (14).

### Chromaffin Cells

To obtain chromaffin cells, adrenal glands from 8- to 12-wk-old mice were incubated in Locke's solution containing 1 mg/ml collagenase (>200 U/ml; Biochrom KG, Berlin, Germany) (36). Cells were resuspended in HEPES-buffered Tyrode's solution (for determination of catecholamine release) or in enriched DMEM and plated on glass coverslips (for electrophysiological experiments). Enriched DMEM (Linaris, Wertheim, Germany) contained: 2.2 g/liter NaHCO<sub>3</sub>, 4.5 g/liter D-glucose, 1.028 g/liter L-glutamine, 10 ml/liter insulin-transferrin-selenium-X (Life Technologies, Inc., Gaithersburg, MD), penicillin and streptomycin (Life Technologies, Inc.). For detection of  $\alpha_2$ -adrenoceptor expression, RNA was isolated from 100–150 chromaffin cells using the RNAqueous 4PCR kit (Ambion, Austin, TX). RT-PCR was performed with 0.2  $\mu$ g of RNA as described previously (35, 37, 38).

### Electrophysiological Measurements and Determination of [Ca<sup>2+</sup>]<sub>i</sub>

The bath solution contained (in mM): 145 NaCl, 2.8 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 1 mg/ml D-glucose (pH 7.2) (osmolarity, 310 mosmol/liter). After the whole-cell patch was established, the cell was perfused locally with a solution containing: 25 tetraethylammonium chloride, 48 Na-gluconate, 60 Na-acetate, 2.8 K-gluconate, 10 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 HEPES, 1 mg/ml D-glucose, 600 nM tetrodotoxin (pH 7.2) (osmolarity was adjusted to 310 mosmol/liter). The pipette solution contained: 70 Cs-glutamate, 30 CsCl, 8 NaCl, 0.125 CaCl<sub>2</sub>, 32 HEPES, 2 MgATP, 0.3 GTP, 0.5 fura-2 (Molecular Probes, Eugene, OR) (pH 7.2) (osmolarity was adjusted to 300 mosmol/liter). The calculated free [Ca<sup>2+</sup>]<sub>i</sub> was approximately 80 nM.

Conventional whole-cell recordings were performed at 30°C with sylvard-coated 3–5 M $\Omega$  pipettes (Kimax-51; Kimble Products, Vineland, NY) 1–2 d after cell preparation. Access resistance ranged from 5–20 M $\Omega$ . An EPC-9 patch clamp amplifier was used together with the Pulse software package (HEKA Electronics, Lambrecht, Germany). Capacitance measurements were performed using the Lindau-Neher technique as described previously (39). A 1000-Hz, 70-mV peak-to-peak sinusoid voltage stimulus was superimposed onto a direct current holding potential of minus 70 mV. Currents were filtered at 3 kHz and sampled at 12 kHz. A triple depolarization voltage protocol was applied 2 min after the whole-cell configuration was established and after 2-min local perfusion. Peak current was estimated from the first (ramp) depolarization after leak subtraction as indicated in Fig. 2A, right panel. Cell size, leak current, and access resistance were not different between the groups (data not shown).

Fluorescence measurements were conducted as described previously (40).

### Acknowledgments

The authors are indebted to Professor E. Neher (Max Planck Institute, Göttingen, Germany) for critical discussions, to Kerstin Hadamek for technical assistance, and to Dr. Moritz Bünemann for assistance with the electrophysiology and critical discussion throughout this project.

Received January 31, 2003. Accepted May 12, 2003.

Address all correspondence and requests for reprints to: Lutz Hein, Institut für Pharmakologie und Toxikologie, Universität Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany. E-mail: hein@toxi.uni-wuerzburg.de.

This study was supported by the Deutsche Forschungsgemeinschaft (DFG) (in support of L.H. and M.J.L.). G.N. is a Ph.D. student of the International M.D./Ph.D. Program in the Neurosciences at the International Max Planck Research School and holds a fellowship from the DFG (DFG Graduiertenkolleg 521).

M.B. and G.N. have contributed equally to this manuscript.

### REFERENCES

- Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Trendelenburg U 1994 International Union of Pharmacology nomenclature of adrenoceptors. *Pharmacol Rev* 46: 121–136
- Hein L 2001 Transgenic models of  $\alpha_2$ -adrenergic receptor subtype function. *Rev Physiol Biochem Pharmacol* 142:162–185
- Koch WJ, Lefkowitz RJ, Rockman HA 2000 Functional consequences of altering myocardial adrenergic receptor signaling. *Annu Rev Physiol* 62:237–260
- MacMillan LB, Hein L, Smith MS, Piacisk MT, Limbird LE 1996 Central hypotensive effects of the  $\alpha_{2a}$ -adrenergic receptor subtype. *Science* 273:801–803
- Rohrer DK, Kobilka BK 1998 Insights from *in vivo* modification of adrenergic receptor gene expression. *Annu Rev Pharmacol Toxicol* 38:351–373
- Thomas SA, Matsumoto AM, Palmiter RD 1995 Noradrenaline is essential for mouse fetal development. *Nature* 374:643–646
- Thomas SA, Palmiter RD 1997 Impaired maternal behavior in mice lacking norepinephrine and epinephrine. *Cell* 91:583–592
- Hoffman BB, Taylor P 2001 Neurotransmission: the autonomic and somatic motor nervous system. In: Hardman JG, Limbird LE, eds. *Goodman & Gilman's: The pharmacological basis of therapeutics*. 10th ed. New York: McGraw-Hill; 115–154
- Young JB, Landsberg L 1998 Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. *Williams textbook of endocrinology*. 9th ed. Philadelphia: WB Saunders; 665–728
- Anderson DJ, Axel R 1986 A bipotential neuroendocrine precursor whose choice of cell fate is determined by NGF and glucocorticoids. *Cell* 47:1079–1090
- Langer SZ 1974 Presynaptic regulation of catecholamine release. *Biochem Pharmacol* 23:1793–1800
- Starke K 1987 Presynaptic  $\alpha$ -autoreceptors. *Rev Physiol Biochem Pharmacol* 107:73–146
- Altman JD, Trendelenburg AU, MacMillan L, Bernstein D, Limbird L, Starke K, Kobilka BK, Hein L 1999 Abnormal

- regulation of the sympathetic nervous system in  $\alpha_{2A}$ -adrenergic receptor knockout mice. *Mol Pharmacol* 56: 154–161
14. Hein L, Altman JD, Kobilka BK 1999 Two functionally distinct  $\alpha_2$ -adrenergic receptors regulate sympathetic neurotransmission. *Nature* 402:181–184
  15. Trendelenburg AU, Klebroff W, Hein L, Starke K 2001 A study of presynaptic  $\alpha_2$ -autoreceptors in  $\alpha_{2A/D}$ -,  $\alpha_{2B}$ - and  $\alpha_{2C}$ -adrenoceptor-deficient mice. *Naunyn Schmiedeberg Arch Pharmacol* 364:117–130
  16. Brede M, Wiesmann F, Jahns R, Hadamek K, Arnolt C, Neubauer S, Lohse MJ, Hein L 2002 Feedback inhibition of catecholamine release by two different  $\alpha_2$ -adrenoceptor subtypes prevents progression of heart failure. *Circulation* 106:2491–2496
  17. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, Barsh GS, Kobilka BK 1996 Cardiovascular regulation in mice lacking  $\alpha_2$ -adrenergic receptor subtypes b and c. *Science* 273:803–805
  18. Langer SZ 1997 25 Years since the discovery of presynaptic receptors: present knowledge and future perspectives. *Trends Pharmacol Sci* 18:95–99
  19. Starke K 2001 Presynaptic autoreceptors in the third decade: focus on  $\alpha_2$ -adrenoceptors. *J Neurochem* 78: 685–693
  20. Bülbring E, Burn JH, De Elio FJ 1948 The secretion of adrenaline from the perfused suprarenal gland. *J Physiol* 107:222–232
  21. Malméjac J 1955 Action of adrenaline on synaptic transmission and on adrenal medullary secretion. *J Physiol* 130:497–512
  22. Gollasch M, Hescheler J, Spicher K, Klinz FJ, Schultz G, Rosenthal W 1991 Inhibition of  $Ca^{2+}$  channels via  $\alpha_2$ -adrenergic and muscarinic receptors in pheochromocytoma (PC-12) cells. *Am J Physiol* 260:C1282–C1289
  23. Kleppisch T, Ahnert-Hilger G, Gollasch M, Spicher K, Hescheler J, Schultz G, Rosenthal W 1992 Inhibition of voltage-dependent  $Ca^{2+}$  channels via  $\alpha_2$ -adrenergic and opioid receptors in cultured bovine adrenal chromaffin cells. *Pflugers Arch* 421:131–137
  24. Powis DA, Baker PF 1986  $\alpha_2$ -Adrenoceptors do not regulate catecholamine secretion by bovine adrenal medullary cells: a study with clonidine. *Mol Pharmacol* 29: 134–141
  25. Sharma TR, Wakade TD, Malhotra RK, Wakade AR 1986 Secretion of catecholamines from the perfused adrenal gland of the rat is not regulated by  $\alpha$ -adrenoceptors. *Eur J Pharmacol* 122:167–172
  26. Starke K, Gorlitz BD, Montel H, Schumann HJ 1974 Local  $\alpha$ -adrenoceptor mediated feed-back inhibition of catecholamine release from the adrenal medulla. *Experientia* 30:1170–1172
  27. Berkowitz DE, Price DT, Bello EA, Page SO, Schwinn DA 1994 Localization of messenger RNA for three distinct  $\alpha_2$ -adrenergic receptor subtypes in human tissues. Evidence for species heterogeneity and implications for human pharmacology. *Anesthesiology* 81:1235–1244
  28. Perala M, Hirvonen H, Kalimo H, Ala-Uotila S, Regan JW, Akerman KE, Scheinin M 1992 Differential expression of two  $\alpha_2$ -adrenergic receptor subtype mRNAs in human tissues. *Brain Res Mol Brain Res* 16:57–63
  29. Smith C, Moser T, Xu T, Neher E 1998 Cytosolic  $Ca^{2+}$  acts by two separate pathways to modulate the supply of release-competent vesicles in chromaffin cells. *Neuron* 20:1243–1253
  30. Voets T 2000 Dissection of three  $Ca^{2+}$ -dependent steps leading to secretion in chromaffin cells from mouse adrenal slices. *Neuron* 28:537–545
  31. Bünemann M, Bücheler MM, Philipp M, Lohse MJ, Hein L 2001 Activation and deactivation kinetics of  $\alpha_{2A}$ - and  $\alpha_{2C}$ -adrenergic receptor-activated G protein-activated inwardly rectifying  $K^+$  channel currents. *J Biol Chem* 276:47512–47517
  32. Bücheler M, Hadamek K, Hein L 2002 Two  $\alpha_2$ -adrenergic receptor subtypes,  $\alpha_{2A}$  and  $\alpha_{2C}$ , inhibit transmitter release in the brain of gene-targeted mice. *Neuroscience* 109:819–826
  33. Bruhn TO, Rondeel JM, Jackson IM 1998 Thyrotropin-releasing hormone gene expression in the anterior pituitary. IV. Evidence for paracrine and autocrine regulation. *Endocrinology* 139:3416–3422
  34. Krsmanovic LZ, Martinez-Fuentes AJ, Arora KK, Mores N, Navarro CE, Chen HC, Stojilkovic SS, Catt KJ 1999 Autocrine regulation of gonadotropin-releasing hormone secretion in cultured hypothalamic neurons. *Endocrinology* 140:1423–1431
  35. Link RE, Stevens MS, Kulatunga M, Scheinin M, Barsh GS, Kobilka BK 1995 Targeted inactivation of the gene encoding the mouse  $\alpha_{2C}$ -adrenoceptor homolog. *Mol Pharmacol* 48:48–55
  36. Colliver TL, Hess EJ, Ewing AG 2001 Amperometric analysis of exocytosis at chromaffin cells from genetically distinct mice. *J Neurosci Methods* 105:95–103
  37. Sawamura S, Kingery WS, Davies MF, Agashe GS, Clark JD, Kobilka BK, Hashimoto T, Maze M 2000 Antinociceptive action of nitrous oxide is mediated by stimulation of noradrenergic neurons in the brainstem and activation of  $\alpha_{2B}$  adrenoceptors. *J Neurosci* 20:9242–9251
  38. Zou AP, Cowley Jr AW 2000  $\alpha_2$ -Adrenergic receptor-mediated increase in NO production buffers renal medullary vasoconstriction. *Am J Physiol* 279:R769–R777
  39. Gillis KD 1995 Techniques for membrane capacitance measurements. In: Sakmann B, Neher E, eds. *Single-channel recording*. 2nd ed. New York: Kluwer Academic Publishers; 155–198
  40. Zhou Z, Neher E 1993 Mobile and immobile calcium buffers in bovine adrenal chromaffin cells. *J Physiol* 469: 245–273
  41. Carbone E, Carabelli V, Cesetti T, Baldelli P, Hernandez-Guijo JM, Giusta L 2001 G-protein- and cAMP-dependent L-channel modulation. A manyfold system to control calcium entry in neurosecretory cells. *Pflugers Arch* 442:801–813
  42. Philipp M, Brede ME, Hadamek K, Gessler M, Lohse MJ, Hein L 2002 Placental  $\alpha_2$ -adrenoceptors control vascular development at the interface between mother and embryo. *Nat Genet* 31:311–315

